From Alphastreet - Earnings Decoded. Market Intelligence Delivered · Newsdesk · · 1m
Inventiva H1 Results: Cash Runway and NATiV3 at Center
Inventiva's cash runway and NATiV3 trial results drive investor focus after weak H1 earnings.
In brief
Inventiva's cash runway and NATiV3 trial results drive investor focus after weak H1 earnings. Inventiva's cash runway extends to Q2 2027 with potential extension to Q1 2028 if additional funding is secured, pending NATiV3 trial results in Q4 2026. Originally reported by Alphastreet - Earnings Decoded. Market…
Inventiva's H1 Results
Inventiva reported EUR 20,000 revenue for H1 2026, down from EUR 4.454 million in H1 2025.
“EUR 20,000”
R&D Expenses Rise
R&D expenses increased to EUR 46.238 million in H1 2026, reflecting NATiV3 trial progress.
“EUR 46.238 million”
Cash Position
Inventiva has EUR 166.1 million cash and EUR 67.8 million short-term deposits as of June 30, 2026.
“EUR 166.1 million”
Cash Runway Timeline
Base runway extends to end of Q2 2027, with potential extension to Q1 2028 if additional funding secured.
“Q2 2027”
NATiV3 Trial Status
Last patient completed final 72-week visit in NATiV3 on September 2, 2026.
“September 2, 2026”
Next Catalyst
NATiV3 topline results expected in Q4 2026, driving regulatory submission and potential 2028 launch.
“Q4 2026”
The essence
Inventiva's cash runway extends to Q2 2027 with potential extension to Q1 2028 if additional funding is secured, pending NATiV3 trial results in Q4 2026.
